Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Heavenly Pastry Confrontation: Pick Your #1 Sweet Treat! - 2Hezbollah fires over 600 times at Israel, IDF troops over last 24 hours
- 3The Main 15 Applications for Efficiency and Association
- 4See the famous winged horse Pegasus fly in the autumn night sky
- 5Why don’t humans have hair all over their bodies? A biologist explains our lack of fur
- How a toxic self-improvement trend with a funny name took over your feed
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- Cyprus urges hotels to open up, pours funding into tourism
- Carry Nature Inside with These Staggering Plant Decisions
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Kenmore East reacts to their best overall delegation award at WNY Model United Nations General Assembly competition
- How a rare drug made from scientists' blood saves babies from botulism
- Germany's far-right AfD tops poll ahead of Merz's conservatives
- 74 suicide warnings and 243 mentions of hanging: What ChatGPT said to a suicidal teen
